TIP30 is associated with progression and metastasis of prostate cancer

International Journal of Cancer

Volumn 123, Issue 4, 2008, Pages 810-816

  Zhang, Hui ^a   Zhang, Yifen ^a,c   Hai, Ou Duan ^a   Kirley, Sandra D ^a   Lin, Sharron X ^a   McDougal, W Scott ^a   Xiao, Hua ^b   Wu, Chin Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Metastasis; Progression; Prostate cancer; TIP30

Indexed keywords

TAT INTERACTING PROTEIN 30; TRANSACTIVATOR PROTEIN; ACYLTRANSFERASE; ANDROGEN RECEPTOR; HTATIP2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; DISEASE ASSOCIATION; DNA MICROARRAY; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TAT INTERACTING PROTEIN 30 GENE; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CANCER INVASION; CELL GROWTH; DISEASE COURSE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR RECURRENCE;

ACETYLTRANSFERASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 47049109934     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23638     Document Type: Article

References (31)

1. Chua SS, Ma Z, Ngan E, Tsai SY. Cdc25B as a steroid receptor coactivator. Vitam Horm 2004;68:231-56.
2. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-19.
3. Agoulnik IU, Vaid A, Bingman WE, III, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959-67.
4. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
5. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
6. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
7. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2002;6:185-95.
8. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004;64:825-9.
9. Xiao H, Tao Y, Greenblatt J, Roeder RG. A cofactor. TIP30, specifically enhances. HIV-1Tat-activated transcription. Proc Natl Acad Sci USA 1998;95:2146-51.
10. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997;14:2167-73.
11. Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 1999;274:13338-4.
12. NicAmhlaoibh R, Shtivelman E. Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 2001;20:270-5.
13. Whitman S, Wang X, Shalaby R, Shtivelman E. Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol 2000;20:583-93.
14. Xiao H, Palhan V, Yang Y, Roeder RG. TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. Embo J 2000;19:956-63.
15. Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG, Xiao H. TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 2003;63:8763-7.
16. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
18. Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade. B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86-96.
19. Hosohata K, Li P, Hosohata Y, Qin J, Roeder RG, Wang Z. Purification and identification of a novel complex which is involved in androgen receptor-dependenttranscription. Mol Cell Biol 2003;23:7019-29.
20. Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion. Metastasis 1989;9:192-208.
21. Robinson VL, Kauffman EC, Sokoloff MH, Rinker-Schaeffer CW. The basic biology of metastasis. Cancer Treat Res 2004;118:1-21.
22. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H. TIP30 interacts with an estrogen receptor α-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 2004;279:27781-9.
23. Zhao J, Ni H, Ma Y, Dong L, Dai J, Zhao F, Yan X, Lu B, Xu H, Guo Y. TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression. Hum Pathol 2007;38:293-8.
24. Pecha J, Ankrapp D, Jiang C, Tang W, Hoshino I, Bruck K, Wagner KU, Xiao H. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland. Oncogene 2007;26:7423-31.
25. Jiang C, Pecha J, Hoshino I, Ankrapp D, Xiao H. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin. Cancer Res 2007;67:3574-82.
26. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.
27. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.
28. Chen C, Wang XF, Sun L. Expression of transforming growth factor beta (TGF-β) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem 1997;272:12862-7.
29. Sun L, Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 1997;272:25367-72.
30. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92.
31. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004;164:1883-6.